What one share of Xenon Pharmaceuticals holds
We are a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. We are advancing a differentiated product pipeline led by our investigational candidate, azetukalner, which is being studied in multiple Phase 3 studies in epilepsy, major depressive disorder, or MDD, and bipolar depression, or BPD.
Xenon Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$4.73 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$3.91 |
| Cash and investments | $12.87 |
| Book value | $12.84 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2012 | $10.78 | −$3.24 | $0.40 | $33.93 | — | −$67.70 |
| 2013 | $13.62 | $1.91 | $0.08 | −$1.73 | — | −$58.29 |
| 2014 | $7.16 | $3.28 | $0.39 | −$0.32 | — | — |
| 2015 | $1.09 | −$1.10 | $0.04 | −$1.31 | — | $4.24 |
| 2016 | $0.12 | −$1.48 | $0.02 | −$1.28 | — | $3.56 |
| 2017 | $0.02 | −$1.72 | $0.02 | −$1.61 | — | $2.00 |
| 2018 | — | −$1.63 | $0.03 | −$1.81 | — | $3.71 |
| 2019 | $0.26 | −$1.54 | $0.05 | −$0.23 | — | $2.99 |
| 2020 | $0.93 | −$0.81 | $0.08 | −$1.47 | — | $4.67 |
| 2021 | $0.42 | −$1.77 | $0.05 | −$1.64 | — | $10.50 |
| 2022 | $0.16 | −$2.06 | $0.05 | −$1.72 | — | $11.53 |
| 2023 | $0.00 | −$2.73 | $0.08 | −$2.34 | — | $12.31 |
| 2024 | $0.00 | −$3.01 | $0.04 | −$2.37 | — | $9.88 |
| 2025 | $0.09 | −$4.36 | $0.01 | −$3.53 | — | $7.27 |
Common questions about Xenon Pharmaceuticals
How much does one share of Xenon Pharmaceuticals earn?
Over the last 12 months, Xenon Pharmaceuticals lost $4.73 for each share.
Does Xenon Pharmaceuticals pay a dividend?
Xenon Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Xenon Pharmaceuticals’s book value per share?
Xenon Pharmaceuticals’s book value is $12.84 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Xenon Pharmaceuticals have?
Each share of Xenon Pharmaceuticals has $12.87 of cash and investments, as of June 30, 2026.
What is Xenon Pharmaceuticals’s free cash flow per share?
−$3.91 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Xenon Pharmaceuticals bought back shares?
Xenon Pharmaceuticals’s share count rose about 5870% from 2012 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.